biotek instrument acquisit contribut growth
recommend buy rate agil along tp
deriv tp base forward price-to-earnings multipl
adjust ep provid
upsid potenti
estim base follow factor strength
pharma diagnost environment forens market
biotek instrument strong growth
agil revenu
per estim net incom
ep y/i non-gaap net incom
ep y/i adjust ep
estim
million except ep crispidea actual
revenu growth driven strength pharma
clinic diagnost environment forens
market region set pace grow high
single-digit follow mid single-digit growth
asia outsid china europ china grew low singl
digit year
agil expect revenu
non-gaap earn guidanc rang
per share estim top line growth
compani name tickerastock ratingbuyunchangedindustri viewoverweightpositivepric jan week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc| januari
incom statement
result revenu
non-
return invest
per share item
balanc sheet
product perform develop
valuat consensu perform
life scienc appli market group revenu
increas report compar lsag
oper margin year
agil crosslab group revenu grew report
last year acg oper margin year
diagnost genom group dgg gener
revenu report y/i
agil captur market share patholog busi
expand presenc next-gen-sequenc
build oligo api busi year dgg cross
billion-dollar revenu threshold repres
agil busi
quarter agil close acquisit biotek
largest acquisit sinc launch new
agil acquisit biotek complement
earlier acquisit year acea bioscienc
acquisit part grow cell analysi busi
serv biopharma academ research custom
agil cell analysi busi gener
annual revenu compani revenu
grow double-digit rate
agil deliv strong result well
posit futur growth build buy
strategi optimist agil perform
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jan ex-dividend date dec last split factor new per last split date inform agil technolog inc| januari
incom statement
result revenu
non-
return invest
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total revenu growth y/i gross gross develop gener administr sg sg oper oper oper margin interest incom incom incom net incom net outstand dilut ep ep growth annual actual annual actual quarterli inc| januari
 market securities- account receivable- total prepaid expenses- current total current improvements- build improvements- machineri furnitur total fix excess- non-curr defer incom non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current total current long-term defer incom non-curr minor interest liability- total non-curr total prefer stock equity- common stock addit paid-in retain treasuri stock- total capitalization- total total liabil stock balanc sheet itemsactu annual actual quarterli inc| januari
net cash provid oper activ compar
net cash use invest activ compar
net cash use financ activ compar
 goodwil amort loss sale investments- asset write-down restruc costs- oper account account incom taxes- net oper total oper activitiescapit properti plant equipment- sale purchas intang invest market equiti net inc dec loan originated/sold- invest net invest activitiesshort term debt long-term debt total debt short term debt repaid- long-term debt total debt issuanc common common prefer stock dividend financ charg financ net financ floweffect exchang rate chang agil inc| januari
agil deliv strong perform quarter due impecc
perform agil crosslab group diagnost genom
agil revenu increas compar
due strong perform agil crosslab
group diagnost genom group
cog increas compar
total gross margin seem flatten octob
comparison octob
 expens drop compar
sg expens increas compar
oper incom increas compar
oper margin compar
adjust oper margin
compar
interest incom incur compar
interest expens compar
effect tax rate
net incom decreas compar
adjust net incom seen growth
compar
gaap ep increas compar
non-gaap ep increas compar
increas
due
strong perform
agil
crosslab group
diagnost
gaap ep increas
compar
net revenu increas compar
foreign currenc movement unfavor impact ppt
net product revenu improv growth
compar
compar
servic revenu increas compar
servic diagnost genom busi
improv due growth servic revenu throughout busi
increas
compar
cog increment comparison
gross margin flatter end compar
due impact effici gain lower inventori charg favor
currenc impact cost off-set higher wage variabl pay product mix
higher expens relat tariff higher amort expens intang
 expens increas compar
expens incur higher due spend new product
relat busi addit higher wage variabl pay
addit expens relat acquir busi partial off-set favor
currenc movement compar spend period last year
sg expens increas compar
sg expens increas due higher wage variabl pay higher
expens higher transform initi cost impair certain
intang asset unfavor currenc movement
oper incom increas compar
oper margin remain flat comparison
oper margin impact higher wage variabl pay higher
acquisit integr cost higher expens relat tariff higher
transform initi expens off-set oper effici save
favor currenc impact
interest incom drop compar
interest expens decreas compar
incom decreas compar
effect tax rate effect tax rate result
provis incom tax significantli impact discret charg
due extens compani tax incent singapor
net incom improv compar net
incom net incom impact primarili due
singapor restructur tax incent modif complet
respons singapor tax law chang non-gaap net incom increas
compar
gaap ep improv compar
non-gaap ep increas compar
net incom improv
compar
net incom
compar
agil acquir two busi biotek acea combin
purchas price billion consider paid billion agil
fund acquisit use exist cash million debt
august compani complet acquisit biotek
acquisit took place purpos expans cell analysi market
acquisit biotek took place compani stand net revenu
net loss
revenu geographi
 contribut total revenu
europ contribut total revenu
asia pacif region contribut total revenu
revenu type revenu gener instrument last quarter
revenu gener consum servic informat
revenu major market analyt laboratori gener
revenu dx clinic gener revenu
agil
diagnost
well european
team improv
revenu
perform
movement
america
unfavor impact
ppt europ
impact
deliv
diagnost clinic
revenu end-market
agil substanti rise revenu quarter due gain
grew y/i core basi
pharma growth revenu strength bio-pharma
servic chemistri consum nasd
academia government revenu drop compar
environment forens increment revenu due balanc
instrument aftermarket due evolv regul
especi opioid
food decreas revenu compar last year china
stabil run-rat final quarter
chemic revenu hike continu growth
recur servic consum
diagnost clinic end market revenu grew y/i core basi
due healthi perform patholog companion dx
life scienc appli market group lsag
life scienc appli market busi provid application-focus
solut includ instrument softwar enabl custom
identifi quantifi analyz physic biolog properti
substanc product well enabl custom clinic life
scienc research area interrog sampl molecular cellular
lsag revenu increas compar
total revenu increas
compar foreign currenc movement
overal unfavor impact revenu ppt
perform within life scienc appli market busi
led strong growth throughout year pharmaceut market
chemic energi market environment forens market
continu show strong growth
gross margin decreas compar
gross margin remain flat compar
incom oper increas compar
incom oper decreas
compar
oper margin slightli declin compar
oper margin slightli decreas
compar
acquir biotek instrument biotek global leader innov life
scienc instrument serv fast-grow cell analysi market
lsag open new state-of-the-art facil harwel scienc
innov campu oxfordshir uk site focus major
research develop hub laser spectroscopi
compar
remain flat
compar
agil crosslab busi span entir lab extens consum
servic portfolio design improv custom outcom
product categori consum includ gc lc column sampl
prepar product custom chemistri larg select laboratori
instrument suppli servic includ start-up oper train
complianc support softwar servic well asset manag
consult servic help increas custom product
agil crosslab group revenu increas
compar total revenu increas
compar foreign currenc
movement overal unfavor impact revenu ppt
perform agil crosslab busi saw continu growth
key end market strong growth pharmaceut food
gross margin increas compar
gross margin increas compar
incom oper increas compar
incom oper increas
compar
oper margin increas compar
oper margin increas compar
acg grew mid-teen china leverag agil larg instrument
instal base expand compani servic footprint emerg
revenu increas
compar
acg grew mid-
teen china
expand
servic footprint
diagnost genom group dgg
diagnost genom busi includ genom nucleic acid contract
manufactur patholog companion diagnost reagent
partnership busi compris five area activ provid
solut includ reagent instrument softwar consum
enabl custom clinic life scienc research area interrog
sampl cellular molecular level
dcg revenu increas compar
total revenu increas
compar foreign currenc movement
overal unfavor impact revenu ppt
gross margin decreas compar
gross margin decreas compar
incom oper increas compar
incom oper increas
compar
oper margin decreas compar
oper margin remain flat compar
agil receiv approv companion diagnost use
china diagnost may use identifi patient local
first-lin treatment merck co keytruda
compar
approv
use china
revenu expect rang
adjust ep expect rang
dilut share count remain
revenu expect rang
adjust ep expect rang
net interest income/expens net expens
sharehold return dividend anti-dilut share repurchas
minimum author remain repurchas share
revenu expect
rang
revenu expect
rang
adjust ep expect
rang
adjust
ep expect
rang
agil report strong result year growth revenu
due growth led agil crosslab group well pharma clinic
diagnost forens environment agil revenu increas
net incom improv impact tax
holiday singapor non-gaap net incom increas
ep increas non- ep increas
strong result
year
growth revenu
due growth led
group well
lsag increment term revenu growth
increment majorli due strong sale ga chromatographi mass
spectrometri cell analysi take geographi consider europ brought
hike term revenu look forward compani promis
long-term growth opportun bring new product recent
agil crosslab group show revenu growth y/i due
growth servic consum portfolio busi saw strong growth
key end market except diagnost clinic market
dcg revenu increas comparison term
geographi america increas revenu mainli due
strong growth nucleic acid solut
agil strengthen molecular spectroscopi open state- the-
art research develop harwel scienc innov campu
oxfordshir uk
agil continu invest growth introduc new differenti
product servic agil declar quarterli dividend per share
common stock paid januari sharehold
non- reconcili
non- reconcili
non- reconcili
incom statement
result revenu
non-
return invest
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin remain flat comparison due
higher wage variabl pay
revenu growth y/i decreas compar
net margin increas compar due decreas tax rate
ep growth increment compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth agil inc| januari
mrqgross mrqoper mrqr mrqsg mrqcog sale inc| januari
invest flow
sale
mrq
capital-expenditure sale
mrq
cap ex sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn asset agil technolog inc| januari
agil latest twelv month return common equiti agil roe last
averag howev roe hit four-year low octob due declin net margin
due increas tax
agil net margin
agil asset turnov respect
show compani use asset effici
agil financi leverag
respect show compani leverag peak debt
capit structur financ asset
agil oper median return common equiti agil return
common equiti decreas y/i increas y/i
dupont analysi agil above-industri roe encourag high roe driven net margin
leverag median compani healthcar sector return common equiti
agil return common equiti higher sector median recent
return invest capit
capit effici ratio use measur firm abil creat valu stakehold
debt equiti firm expect continu gener posit excess return new invest
futur see valu increas growth increas
agil increas last four fiscal year
agil oper median return invest capit fiscal year
end octob
median compani healthcar sector agil higher
sector median recent period
differ wacc refer econom profit excess return
agil wacc
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item agil technolog inc| januari
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free inc| januari
current price-to-earnings averag price-to-earnings due increas stock price price-to-earnings
trail expect forward price-to-earnings multipl
incom statement
result revenu
non-
return invest
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held institut mutual fund float held institut mutual fund institut hold institut holdersholdershar report outvalueblackrock vanguard group inc price row associ wellington manag compani state mutual automobil insur artisan partner limit geod capit manag nomura hold top mutual fund holdersholdershar report outvaluevanguard total stock market price row mid cap growth vanguard spdr etf vanguard institut fund-institut price row fidel ishar vanguard growth inc| januari
developmentsagil companion diagnost expand ce-ivd mark europ includ head neck squamou cell carcinoma world-wide leader partner pharmaceut compani develop immunohistochemical-bas diagnost cancer pharmdx assay label use hnscc european union agil develop pharmdx collabor merck agil announc new icp-o system innov instrument new gener icp-o system laboratori serv environment food energi chemic materi market greater instrument intellig enabl lab avoid unplan downtim take pro-act approach reduc need remeasur samplesagil open state-of-the-art spectroscopi open new state-of-the-art facil spectroscopi research develop harwel scienc innov campu oxfordshir uk leader molecular spectroscopi new agil site major research develop hub laser spectroscopi also incorpor agil raman spectroscopi busi formerli known cobalt light system agil nuh launch new translat hub boost clinic nation univers singapor global leader life scienc diagnost appli chemic market nation univers hospit nuh establish singapor first integr translat hub leverag biochem innov research data analyt develop new method translat clinic research clinic diagnost inc| januari
incom statement
result revenu
non-
return invest
per share item
balanc sheet
product perform develop
valuat consensu perform
consensu view analyst trend stock
forecast agil
compar
forward price-to-earnings
compar
consensu view analyst trend stock
averag revenu estim
current qtr next
qtr
sale growth
estim
averag revenu estim
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last daysobsoleteobsoleteobsoleteobsoletedown last dayscurr surprisescurr growth rate agil technolog inc| januari
incom statement
result revenu
non-
return invest
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price show slight increment period surg decemb
later increas end decemb
averag volum trade quarter
stock price volatil year increment
rang stock stock surg januari
later show huge fluctuat current trade
stock price show upward trend past gave return past
stock gave huge return past due perform growth past
agil deliv strong result year growth revenu growth adjust ep
total revenu adjust ep expect tp reach
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
